Patents by Inventor Albert Frederick Candia, III

Albert Frederick Candia, III has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Toll-like receptor antagonist compounds and methods of use
    Patent number: 11827641
    Abstract: The invention relates to compounds of formula (I): or a salt or solvate thereof, wherein the variables are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are antagonists of toll-like receptors such as TLR7, TLR8 and/or TLR9 that are useful for inhibiting immune response and treating diseases associated with undesirable immune response.
    Type: Grant
    Filed: May 20, 2022
    Date of Patent: November 28, 2023
    Assignee: DYNAVAX TECHNOLOGIES CORPORATION
    Inventors: Albert Frederick Candia, III, Richard Thomas Beresis, Robert L. Coffman
  • Toll-like receptor antagonist compounds and methods of use
    Patent number: 11370794
    Abstract: The invention relates to compounds of formula (I): or a salt or solvate thereof, wherein the variables are as described herein. Compounds of formula (I), and pharmaceutical compositions thereof, are antagonists of toll-like receptors such as TLR7, TLR8, and/or TLR9. In certain embodiments, compounds of the invention are useful for inhibiting immune response and treating diseases associated with undesirable immune response.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: June 28, 2022
    Assignee: DYNAVAX TECHNOLOGIES CORPORATION
    Inventors: Albert Frederick Candia, III, Richard Thomas Beresis, Robert L. Coffman
  • TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE
    Publication number: 20190345161
    Abstract: The invention relates to compounds of formula (I): or a salt or solvate thereof, wherein the variables are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are antagonists of toll-like receptors such as TLR7, TLR8 and/or TLR9 that are useful for inhibiting immune response and treating diseases associated with undesirable immune response.
    Type: Application
    Filed: November 9, 2017
    Publication date: November 14, 2019
    Applicant: Dynavax Technologies Corporation
    Inventors: Albert Frederick CANDIA, III, Richard Thomas BERESIS, Robert L. COFFMAN
  • Nucleic acid molecule encoding a CLASP-2 transmembrane protein
    Patent number: 7459308
    Abstract: The present invention relates to a cell surface molecules, designated cadherin-like asymmetry proteins (“CLASPs”). In particular, it relates to CLASP-2 polynucleotides, polypeptides, fusion proteins, and antibodies. The invention also relates to methods of modulating an immune response by interfering with CLASP function.
    Type: Grant
    Filed: September 15, 2003
    Date of Patent: December 2, 2008
    Assignee: Arbor Vita Corporation
    Inventors: Peter S. Lu, Jonathan David Garman, Albert Frederick Candia, III